User profiles for MARIE ALT
Marie T. AltPhD Student, Department of Microsystems Engineering Verified email at imtek.de Cited by 210 |
Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials
…, A Vincent-Salomon, N Servant, M Alt… - Journal of the …, 2016 - academic.oup.com
With the advent of high-throughput molecular technologies, several precision medicine (PM)
studies are currently ongoing that include molecular screening programs and PM clinical …
studies are currently ongoing that include molecular screening programs and PM clinical …
Immunotherapy in head and neck cancers: a new challenge for immunologists, pathologists and clinicians
S Outh-Gauer, M Alt, C Le Tourneau, J Augustin… - Cancer Treatment …, 2018 - Elsevier
Cancer occurrence can be understood as the result of dysfunctions in immune tumoral
microenvironment. Here we review the recent understandings of those microenvironment changes…
microenvironment. Here we review the recent understandings of those microenvironment changes…
Enfortumab Vedotin in urothelial cancer
M Alt, C Stecca, S Tobin, DM Jiang… - … advances in urology, 2020 - journals.sagepub.com
The treatment landscape for metastatic urothelial cancer (mUC) beyond first-line platinum-based
chemotherapy has changed significantly over the last 5 years with the recent approvals …
chemotherapy has changed significantly over the last 5 years with the recent approvals …
Hybrid surface design for robust superhydrophobicity
Surfaces may be rendered superhydrophobic by engineering the surface morphology to
control the extent of the liquid–air interface and by the use of low-surface-energy coatings. The …
control the extent of the liquid–air interface and by the use of low-surface-energy coatings. The …
First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/anti-VEGF-A antibody, in adult patients with advanced solid …
…, V Boni, A Taus, J Albanell, MP Sablin, M Alt… - Clinical Cancer …, 2018 - AACR
Purpose: Vanucizumab is an investigational antiangiogenic, first-in-class, bispecific mAb
targeting VEGF-A and angiopoietin-2 (Ang-2). This first-in-human study evaluated the safety, …
targeting VEGF-A and angiopoietin-2 (Ang-2). This first-in-human study evaluated the safety, …
Let there be light—optoprobes for neural implants
MT Alt, E Fiedler, L Rudmann, JS Ordonez… - Proceedings of the …, 2016 - ieeexplore.ieee.org
Over the past decades, optical technologies have entered neural implant technologies.
Applications such as optogenetics, near-infrared spectroscopy (NIRS), and direct-near-infrared …
Applications such as optogenetics, near-infrared spectroscopy (NIRS), and direct-near-infrared …
[HTML][HTML] Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie
C Basse, C Morel, M Alt, MP Sablin, C Franck… - ESMO open, 2018 - Elsevier
Background High throughput molecular screening techniques allow the identification of multiple
molecular alterations, some of which are actionable and can be targeted by molecularly …
molecular alterations, some of which are actionable and can be targeted by molecularly …
[HTML][HTML] Recent advances in the management of penile cancer: a contemporary review of the literature
CE Stecca, M Alt, DM Jiang, P Chung, JM Crook… - Oncology and …, 2021 - Springer
Penile cancer is a rare condition, which mostly affects men in their sixth decade of life. The
most common histology is squamous cell carcinoma (SCC), with about half of the cases …
most common histology is squamous cell carcinoma (SCC), with about half of the cases …
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell …
…, F Rolland, M Chausson, E Borcoman, M Alt… - Investigational new …, 2021 - Springer
Background The phosphatidylinositol-3 kinase pathway is often altered in head and neck
squamous cell carcinoma (HNSCC), and is involved in the resistance to EGFR inhibitors. …
squamous cell carcinoma (HNSCC), and is involved in the resistance to EGFR inhibitors. …
[HTML][HTML] The spectrum of clinical trials aiming at personalizing medicine
C Le Tourneau, M Kamal, M Alt… - Chinese clinical …, 2014 - cco.amegroups.org
All anticancer molecularly targeted agents on the market today have been approved with
one or no companion diagnostic based on a specific genomic molecular alteration. These …
one or no companion diagnostic based on a specific genomic molecular alteration. These …